CLOs on the Move

Saranas

www.saranas.com

 
Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.saranas.com
  • 3900, Essex Lane
    Houston, TX USA 77027
  • Phone: 650.219.4111

Executives

Name Title Contact Details

Similar Companies

Teva Canada

Teva Canada is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Greenrise Global Brands

Greenrise is a Canadian publicly traded corporation with its representative office located in Hamburg, Germany and operates in the medical and CBD cannabis markets in Germany.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.

KeySource

enter your site description here

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus` investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.